Takeda, Baxter expand vax collaboration; J&J offers $2.3B for Crucell;

Vaccine Research 

> Takeda and Baxter "will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market." Report

> The FDA has given Bavarian Nordic the green light to launch a late stage trial of its prostate cancer vaccine. Story

> In a research report presented in the December 2010 issue of the Journal of Leukocyte Biology, scientists from Singapore show that Mycobacterium chelonae, a common environmental bacterium found in soil and water, can decrease the effectiveness of the bacille Calmette-Guerin (BCG) vaccine used to prevent tuberculosis, especially in countries outside of the United States. Release

Vaccine Market

> J&J has formally offered $2.3 billion to acquire the Dutch vaccine maker Crucell. The two companies agreed on the buyout last October. If the deal proceeds as planned, J&J's vaccine gambit will qualify as its biggest acquisition in four years. Article

> Canadian health officials are calling for a national vaccination strategy, saying it's time to do away with the "patchwork" approach that has been in use. Story

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.